Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.

Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.

Item
http://www.wikidata.org/entity/Q46556588
Pre-treatment risk stratification of prostate cancer patients: A critical review.High-risk prostate cancer-classification and therapy.Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapyCurrent prostate cancer: 20 years later.Predictive models in external beam radiotherapy for clinically localized prostate cancer.Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapyNew tricks with old dogs: personalised medicine and clinical trialsPET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort.Fatigue and other adverse effects in men treated by pelvic radiation and long-term androgen deprivation for locally advanced prostate cancer.Adding intensity-modulated radiotherapy to the pelvis does not worsen the adverse effect profiles compared to limited field radiotherapy in men with prostate cancer at 12-month follow-up.Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life.Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy
P2860

Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials.

Item
http://www.wikidata.org/entity/Q46556588
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Defining high risk prostate ca ...... for designing clinical trials.
@en
Defining high risk prostate ca ...... for designing clinical trials.
@nl
type
label
Defining high risk prostate ca ...... for designing clinical trials.
@en
Defining high risk prostate ca ...... for designing clinical trials.
@nl
prefLabel
Defining high risk prostate ca ...... for designing clinical trials.
@en
Defining high risk prostate ca ...... for designing clinical trials.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P356
P1433
P1476
Defining high risk prostate ca ...... for designing clinical trials.
@en
P2093
P304
P31
P356
10.1016/J.JURO.2006.06.081
P407
P433
P478
P50
P577
P698